Forecasting The Future: 6 Analyst Projections For Quest Diagnostics
Benzinga Insights 9 months ago
Analyst Ratings
Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Quest Diagnostics (NYSE:DGX) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 1 | 4 | 0 | 0 |
| Last 30D | 1 | 1 | 3 | 0 | 0 |
| 1M Ago | 0 | 0 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $218.33, with a high estimate of $225.00 and a low estimate of $210.00. This upward trend is apparent, with the current average reflecting a 9.17% increase from the previous average price target of $200.00.
Breaking Down Analyst Ratings: A Detailed Examination
The standing of Quest Diagnostics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| David Macdonald | Truist Securities | Raises | Hold | $220.00 | $205.00 |
| Kevin Caliendo | UBS | Raises | Neutral | $210.00 | $190.00 |
| Elizabeth Anderson | Evercore ISI Group | Raises | In-Line | $220.00 | $190.00 |
| Stephanie Davis | Barclays | Raises | Overweight | $225.00 | $210.00 |
| Tycho Peterson | Jefferies | Raises | Buy | $220.00 | $215.00 |
| Patrick Donnelly | Citigroup | Raises | Neutral | $215.00 | $190.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Quest Diagnostics. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Quest Diagnostics compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Quest Diagnostics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Quest Diagnostics analyst ratings.
All You Need to Know About Quest Diagnostics
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Financial Milestones: Quest Diagnostics's Journey
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining Quest Diagnostics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 13.18% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Quest Diagnostics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 8.63%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Quest Diagnostics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.36% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.51%, the company showcases effective utilization of assets.
Debt Management: Quest Diagnostics's debt-to-equity ratio stands notably higher than the industry average, reaching 0.88. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
The Core of Analyst Ratings: What Every Investor Should Know
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.